| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $469K | +153.5% | +228.0% |
| SG&A Expense | $718K | -15.9% | -28.7% |
| Operating Income | -$1.2M | -14.2% | -3.2% |
| Net Income | -$1.2M | -10.3% | -2.8% |
| EPS (Basic) | -$0.55 | +12.7% | +21.4% |
| EPS (Diluted) | -$0.55 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.9M | -32.7% | +15.2% |
| Accounts Receivable | $0 | -100.0% | — |
| Current Assets | $2.7M | -28.2% | -24.4% |
| Total Assets | $3.7M | -21.4% | +4.9% |
| Current Liabilities | $921K | -14.2% | +11.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.3M | — | — |
| Capital Expenditures | $97K | — | — |
| Investing Cash Flow | -$97K | — | — |
| Financing Cash Flow | $3.3M | — | — |
| Free Cash Flow | -$2.4M | — | — |
| +21.4% |
| $921K |
| -14.2% |
| +11.5% |
| Stockholders' Equity | $2.8M | -23.4% | +2.9% |